Small-batch research peptidesThird-party tested for purityDispatched within 24 hoursEvery lot on the recordFree US shipping over $15010% off your first orderFor research use only
Small-batch research peptidesThird-party tested for purityDispatched within 24 hoursEvery lot on the recordFree US shipping over $15010% off your first orderFor research use only
CJC-1295 / Ipamorelin
Also known as Mod GRF 1-29 + Ipamorelin (No DAC)
GH-axis research blend — A combination engineered to enhance GH release through synchronized GHRH and ghrelin-receptor activation in experimental research models.
Purity specification: 99%+Lyophilized powder
From $99.99In stock
View purchase options
Specifications
| CAS number | 863288-34-0 / 170851-70-4 |
|---|
| Molecular formula | Blend |
|---|
| Molecular weight | 3367.97 + 711.85 g/mol |
|---|
| Form | Lyophilized powder |
|---|
Research use only. Not for human or veterinary use, consumption, diagnosis, treatment, or therapeutic purposes.
Documentation
Certificates of Analysis
Batch-specific, third-party lab certificates. Each COA is published here once its lot has been tested — preview the results, then open the full PDF.
No released lot-specific certificates are currently published for this compound. A certificate appears only after its batch clears release and the source PDF is available.
View the compound COA record →
Research context
Sources and references
What literature relates to the CJC-1295 / Ipamorelin blend?
The blend combines two distinct research compounds. References are separated by constituent because studies of either constituent are not evidence for the combined commercial preparation.
Human pharmacology study
Teichman SL, Neale A, Lawrence B, et al. Journal of Clinical Endocrinology & Metabolism (2006).
Characterizes CJC-1295 as a GHRH analog; it does not evaluate Astral's blend.
PMID 16352683 · DOI 10.1210/jc.2005-1536
Preclinical pharmacology study
Raun K, Hansen BS, Johansen NL, et al. European Journal of Endocrinology (1998).
Characterizes ipamorelin receptor activity and selectivity; it does not evaluate the blend.
PMID 9849822 · DOI 10.1530/eje.0.1390552
Editorially curated and source-verified; not independently peer-reviewed by Astral. Last source check: 2026-07-21. How sources are selected.
Read the compound research page →